Current treatment of Hodgkin's disease

Critical Reviews in Oncology/Hematology

Volumn 35, Issue 1, 2000, Pages 49-73

  Eghbali, Houchingue ^a   Soubeyran, Pierre ^a   Tchen, Nadine ^a   De Mascarel, Isabelle ^a   Soubeyran, Isabelle ^a   Richaud, Pierre ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADJUVANT CHEMOTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; HODGKIN DISEASE; HUMAN; LYMPHANGIOGRAPHY; PROGNOSIS; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; FEMALE; HODGKIN DISEASE; HUMANS; MALE; PREGNANCY; RADIOTHERAPY;

EID: 0034119390     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(99)00070-0     Document Type: Review

References (332)

1. Wolf J., Bohlen H., Diehl V. Report on the workshop biology. Third International Symposium on Hodgkin's Lymphoma, Cologne, 1995. Ann. Oncol. 7(suppl 4):1995;S45-S47.
2. Frizzera G., Morane E.M., Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet. 1:1974;1070-1073.
3. Lukes R.J., Tindle B.H. Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin's disease. N. Engl. J. Med. 292:1975;1-8.
4. Stein H., Masson D.Y., Gerdes J. et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 66:1985;848-848.
5. Chan J.K., Banks P.M., Cleary M.L. et al. A proposal for classification of lymphoid neoplasms (by the International Lymphoma Study Group). Histopathology. 25:1994;517-536.
6. Harris N.L., Jaffe E.S., Stein H. et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 84:1994;1361-1392.
7. Rosenberg S.A., Kaplan H.S. Evidence for an orderly progression in the spread of Hodgkin's disease. Cancer. 26:1966;1225-1231.
8. Jones S.E. The staging of Hodgkin's disease. Med. Oncol. Tumor Pharmacother. 1:1984;15-17.
9. Leibenhaut M.H., Hoppe R.T., Efron B. et al. Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease. J. Clin. Oncol. 7:1989;81-91.
10. Mauch P., Larsen D., Osteen R. et al. Prognostic factors for predictive surgical staging in patients with Hodgkin's disease. J. Clin. Oncol. 8:1990;257-265.
11. Mauch P., Somers R. Controversies in the use of diagnostic staging laparotomy and splenectomy in the management of Hodgkin's disease. Ann. Oncol. 3(suppl 4):1992;41-43.
12. Bergsagel D.F., Alison R.E., Bean H.A. et al. Results of treating Hodgkin's disease without a policy of laparotomy staging. Cancer Treat. Rep. 66:1982;717-731.
13. Tubiana M., Henry-Amar M., Carde P. et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The E.O.R.T.C. lymphoma group controlled clinical trials: 1964-1987. Blood. 73:1989;47-56.
14. Sutcliffe S.B., Gospodarowicz M.K., Bergsagel D.E. et al. Prognostic factors for management of localized Hodgkin's disease. J. Clin. Oncol. 3:1985;393-401.
15. Dietrich P.Y., Henry-Amar M., Cosset J.M. et al. Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen? Blood. 84:1994;1209-1215.
16. Kaldor J.M., Day N.E., Clarke E.A. et al. Leukemia following Hodgkin's disease. N. Engl. J. Med. 322:1990;7-13.
17. Tura S., Fiacchini M., Zinzani P.L. et al. Splenectomy and the increase risk of secondary acute leukemia in Hodgkin's disease. J. Clin. Oncol. 11:1993;925-930.
18. Castellino R.A. Imaging techniques for staging abdominal Hodgkin's disease. Cancer Treat. Rep. 66:1982;697-700.
19. Castellino R.A., Dunnick N., Goffinet D.R. et al. Predictive value of lymphography for sites of subdiaphragmatic disease encountered at staging laparotomy in newly diagnosed Hodgkin's disease. J. Clin. Oncol. 1:1983;532-536.
20. Castellino R.A., Gofinet D.R., Blank N. et al. Computed tomography, lymphography and staging laparotomy: correlation in initial staging of Hodgkin's disease. Am. J. Roentgenol. 143:1984;37-41.
21. Carde P. Diagnostic procedures in Hodgkin's disease. Diehl V. Hodgkin's disease. Baillière Clinical Haematol. 9(3):1996;479-501.
22. Castellino R.A. Diagnostic imaging studies in patients with newly diagnosed Hodgkin's disease. Ann. Oncol. 3(suppl 4):1992;45-47.
23. Maublant J., Vuillez J.P., Talbot J.N. et al. Tomographie par émission de positons (TEP) et [F-18]-fluorodésoxyglucose (FDG) en cancérologie. Bull. Cancer. 85:1998;935-950.
24. Carr R., Barrington S.F., Madan B. et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood. 91:1998;3340-3346.
25. Moog F., Bangerter M., Kotzerke J. et al. 18-F-fluorodeosxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J. Clin. Oncol. 16:1998;603-609.
26. de Wit M., Bumman D., Beyer W. et al. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann. Oncol. 8(suppl 1):1997;S57-S60.
27. Bangerter M., Griesshammer M., Binder T. et al. New diagnostic imaging procedures in Hodgkin's disease. Ann. Oncol. 7(suppl 4):1996;S55-S59.
28. Bangerter M., Moog F., Buchman I. et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann. Oncol. 9:1998;1117-1122.
29. Hagemeister F., Fesus S.M., Lamki L.M. et al. Role of gallium scan in Hodgkin's disease. Cancer. 65:1990;1090-1096.
30. Hagemeister F.B., Purugganan R., Podoloff D.A. et al. The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy. Ann. Oncol. 5(suppl 2):1994;59-63.
31. Devizzi L., Maffioli L., Bonfante V. et al. Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease. Ann. Oncol. 8(suppl 1):1997;53-56.
32. Salloum E., Schwab Brandt D., Caride V.J. et al. Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients. J. Clin. Oncol. 15:1997;518-527.
33. Cooper D.L., Caride V.J., Zloty M. et al. Gallium scans in patients with mediastinal Hodgkin's disease treated with chemotherapy. J. Clin. Oncol. 11:1993;1092-1098.
34. Munker R., Stengel A., Stabler A. et al. Diagnostic accuracy of ultrasound and computed tomography in the staging of Hodgkin's disease. Verification by laparotomy in 100 cases. Cancer. 76:1995;1460-1466.
35. Gerrit C.J.H., van Overhagen H., van Lom K. et al. Ultrasound examination of pathological cervical lymph nodes in patients with non-Hodgkin's lymphoma and Hodgkin's disease. Br. J. Haematol. 88:1994;626-628.
36. Henry-Amar M., Friedman S., Hayat M. et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin's disease. Ann. Intern. Med. 114:1991;361-365.
37. Munker R., Hasenclever D., Brosteanu O. et al. Bone marrow involvement in Hodgkin's disease: an analysis of 135 consecutive cases. German Hodgkin's Lymphoma Study Group [see comments]. J. Clin. Oncol. 13:1995;403-409.
38. Mahoney D.H., Schreuders Jr L.C., Gresik M.V. et al. Role of bone marrow examination in children with Hodgkin's disease. Med. Pediatr. Oncol. 30:1998;175-177.
39. Eghbali H, Bonichon F, Bonnel C, et al. Clinical features predicting bone marrow involvement in Hodgkin's disease: attempt to avoid unnecessary investigations in favourable presentations. Fifth International Conference on Malignant Lymphoma. June 9-12, 1993 (abstract P66).
40. Abrahamsen A.F., Jakobsen E., Langholm R. et al. Bone marrow examination in Hodgkin's disease. Acta Oncol. 31:1992;41-42.
41. Warnke R.A., Weiss L.M., Chan J.K.C. et al. Tumors of the lymph nodes and spleen. Rosai J., Sobin L.H. Atlas of Tumor Pathology. 1995;277-304 Armed Forces Institute of Pathology, Washington DC.
42. Lukes R.J., Butler J.J. The pathology and nomenclature of Hodgkin's disease. Cancer Res. 26:1966;1063-1081.
43. Eghbali H., Petorin C., de Mascarel I. et al. Maladie de Hodgkin type 4 à dépletion lymphoïde. Révision anatomoclinique de 35 cas. Bull. Cancer (Paris). 81:1994;866-870.
44. Tubiana M., Henry-Amar M., Burgers M.V. et al. Prognostic significance of erythrocyte sedimentation rate in clinical stages I-II of Hodgkin's disease. J. Clin. Oncol. 2:1984;194-200.
45. Friedman S., Henry-Amar M., Cosset J.M. et al. Evolution of erythrocyte sedimentation rate as predictor of early relapse in posttherapy early-stage Hodgkin's disease. J. Clin. Oncol. 6:1988;596-602.
46. Henry-Amar M., Friedman S., Hayat M. et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin's disease. Ann. Intern. Med. 114:1991;361-365.
47. Rosenberg S.A. Report of the committee on the staging of Hodgkin's disease. Cancer Res. 26:1966;1310.
48. Carbone P.P., Kaplan H.S., Musshoff K. et al. Report of the committee on Hodgkin's disease staging classification. Cancer. Res. 31:1971;1860-1861.
49. Kaplan H.S. Hodgkin's disease. 2nd edn:1980;Harvard University Press, Cambridge.
50. Kennedy B.J., Loeb V., Peterson V.M. et al. National survey of patterns of care for Hodgkin's disease. Cancer. 56:1985;2547-2556.
51. Gobbi P.G., Cavalli C., Federico M. et al. Hodgkin's disease prognosis: a directly predictive equation. Lancet. i:1988;675-679.
52. Peckham M.J., Ford H.T., McElwain J.T. et al. The results of radiotherapy for Hodgkin's disease. Br. J. Cancer. 32:1975;391-400.
53. Carmel R.J., Kaplan H.S. Mantle irradiation in Hodgkin's disease. Cancer. 37:1976;2813-2825.
54. Desser R.K., Golomb H.M., Ultmann J.F. et al. Prognostic classification of Hodgkin's disease in pathologic stage III, based on anatomic considerations. Blood. 49:1977;833-893.
55. Levi J.A., Wiernik P.H. Limited extranodal Hodgkin's disease. Unfavorable prognosis and therapeutic implications. Am. J. Med. 63:1977;365-372.
56. Thar T.L., Million R.R., Haussner R.J. et al. Hodgkin's disease, stages I and II. Relationship of recurrence to size of disease, radiation dose, and number of sites involved. Cancer. 43:1979;1101-1105.
57. Golomb H.M., Sweet D., Ultman J.E. et al. Importance of substaging of stage III Hodgkin's disease. Semin. Oncol. 7:1980;136-143.
58. Lee C.K.K., Bloomfield C.D., Goldman A.I. et al. Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy. Cancer. 46:1980;2403-2409.
59. Hoppe R.T., Coleman C.N., Cox R.S. et al. The management of stage I II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience. Blood. 59:1982;455-465.
60. Liew K.H., Easton D., Horwich A. et al. Bulky mediastinal Hodgkin's disease management and prognosis. Hematol. Oncol. 2:1984;45-59.
61. Tubiana M., Henry-Amar M., Hayat M. et al. The EORTC treatment of early stages of Hodgkin's disease: the role of radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 10:1984;197-210.
62. Tubiana M., Henry-Amar M., Van der Werf-Messing B. et al. A multivariate analysis of prognostic factors in early stage Hodgkin's disease. Int J Radiat Oncol Biol Phys. 11:1985;23-30. For the Radiotherapy-Chemotherapy Group of the EORTC.
63. Mauch P.M., Goffman T., Rosenthal D.S. et al. Stage III Hodgkin's disease: improved survival with combined modality treatment as compared with radiation therapy alone. J. Clin. Oncol. 3:1985;1166-1173.
64. Pillai G.N., Hagemeister F.B., Velasquez W.S. et al. Prognostic factors for stage IV Hodgkin's disease treated with MOPP, with or without bleomycin. Cancer. 55:1985;691-697.
65. Leslie N.T., Mauch P.M., Hellman S. Stage IA to IIB supradiaphragmatic Hodgkin's disease. Long-term survival and relapse frequency. Cancer. 55:1985;2072-2078.
66. Longo D.L., Young R.C., Wesley M. et al. Twenty years of MOPP therapy for Hodgkin's disease. J. Clin. Oncol. 4:1986;1295-1306.
67. Lee C.K.K., Aeppli D.M., Bloomfield C.D. et al. Hodgkin's disease: a reassessment of prognostic factors following modification of radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 13:1987;983-991.
68. Farah R., Golomb H.M., Hallahan D.E. et al. Radiation therapy for pathologic stage III Hodgkin's disease with and without chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 17:1989;761-766.
69. Selby P., Patel P., Milan S. et al. ChlVPP combination chemotherapy for Hodgkin's disease: long term results. Br. J. Cancer. 62:1990;279-285.
70. Meerwaldt JH, van Glabbeke M, Vaughan-Hudson. Prognostic factors for stage I and II Hodgkin's disease. In: Somers R., Henry-Amar M, Meerwaldt JK, Carde P, editors. Colloque INSERM, vol. 196. Treatment strategy in Hodgkin's disease. Paris: John Libbey Eurotext, 1990. p. 37-50.
71. Lee C.K.K., Aeppli D.M., Bloomfield C.D. et al. Curative radiotherapy for laparotomy-staged IA, IIA, IIIA Hodgkin's disease: an evaluation of the gains achieved with radical radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 19:1990;547-559.
72. Löffler M, Dixon DO, Swindell R. Treatment strategy in Hodgkin's disease. In: Somers R, Henry-Amar M, Meerwaldt JK, Carde P, editors. Colloque INSERM, vol. 196. Treatment strategy in Hodgkin's disease. Paris: John Libby Eurotext, 1990:89-103.
73. Levi J.A., Wiernik P.H., O'Connell M.J. Patterns of relapse in stage I,II and IIIA Hodgkin's disease: influence of initial therapy and implications for the future. Int. J. Radiat. Oncol. Biol. Phys. 2:1977;853-862.
74. Löffler M., Pfreundschuh M., Hasenclever D. et al. Prognostic risk factors in advanced Hodgkin's lymphoma. Report of the German Hodgkin Study Group. Blut. 56:1988;273-281.
75. Mauch P.M., Goodman R., Hellman S. The significance of mediastinal involvement in early stages Hodgkin's disease. Cancer. 42:1978;1038-1045.
76. Velentjas E., Barrett A., McElwain J.T. et al. Mediastinal involvement in early-stage Hodgkin's disease. Response to treatment and pattern of relapse. Eur. J. Cancer. 16:1980;1065-1068.
77. Fuller L.M., Gamble J.F., Velazquez W.S. et al. Evaluation of the significance of prognostic factors in stage III Hodgkin's disease treated with MOPP and radiotherapy. Cancer. 45:1980;1352-1364.
78. Fuller L.M., Madoc-Jones H., Hagemeister F.B. et al. Furher follow-up of results of treatment in 90 laparotomy-negative stage I and stage II Hodgkin's disease patients: significance of medistinal and non-mediastinal presentations. Int. J. Radiat. Oncol. Biol. Phys. 6:1980;799-808.
79. Prosnitz L.R., Curtis A.M., Knowlton A.H. et al. Supradiaphragmatic Hodgkin's disease: significance of large mediastinal masses. Int. J. Radiat. Oncol. Biol. Phys. 6:1980;809-813.
80. Mauch P.M., Gorshein D., Cunningham J. et al. Influence of mediastinal adenopathy on site and frequency of relapse in patients with Hodgkin's disease. Cancer. 66:1982;809-817.
81. Nissen N.I., Nordentoft A.M. Radiotherapy versus combined modality treatment of stage I and II Hodgkin's disease. Cancer Treat. Rep. 66:1982;799-803.
82. North L.B., Fuller L.M., Hagemeister F.B. et al. Importance of initial mediastinal adenopathy in Hodgkin's disease. Am. J. Rad. 138:1982;229-235.
83. Mazza P., Lauria F., Sciascia R. et al. Prognostic significance of large mediadtinal involvement in Hodgkin's disease. Scand. J. Haematol. 31:1983;315-321.
84. Dorreen M.S., Wrigley P.F.M., Laidlow J.M. et al. The management of stage II supradiaphragmatic Hodgkin's disease at St. Bartolomew's hospital. Cancer. 54:1984;2882-2888.
85. Crowther D., Wagstaff J., Deakin D. et al. A randomized study comparing chemotherapy alone with chemotherapy followed by radiotherapy in patients with pathologically staged IIIA Hodgkin's disease. J. Clin. Oncol. 2:1984;892-897.
86. Anderson H., Deakin D.P., Wagstaff J. et al. A randomised study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin's disease PS IA-IIA: a report from the Manchester lymphoma group. Br. J. Cancer. 49:1984;695-702.
87. Anderson H., Jenkins J.P.R., Brigg D.J. et al. The prognostic significance of medistinal bulk in patients patients with stage IA-IVB Hodgkin's disease: a report from the Manchester Lymphoma Group. Clin. Radiol. 36:1985;449-454.
88. Schomberg P.J., Evans R.G., O'Connell M.J. et al. Prognostic significance of mediastinal mass in adult Hodgkin's disease. Cancer. 53:1984;324-328.
89. Zagars G., Rubin P. Laparotomy-staged IA versus IIA Hodgkin's disease. A comparative study with evaluation of prognostic factors for stage IIA disease. Cancer. 56:1985;864-873.
90. Ferrant A., Hamoir V., Binon J. et al. Combined modality treatment for mediastinal Hodgkin's disease. Prognostic significance of constitutional symptoms and size of disease. Cancer. 55:1985;317-322.
91. Gospodarowicz M.K., Sutcliffe S.B., Bergsagel D.E. et al. Radiation therapy in clinical stage I and II Hodgkin's disease. Eur. J. Cancer. 28A:1992;1841-1846.
92. Hoppe R.T., Horning S.J., Rosenberg S.A. the concept, evolution and preliminary result of the current Stanford clinical trials for Hodgkin's disease. Cancer Surv. 4:1985;459-475.
93. Crnkovich M.J., Leopold K., Hoppe R.T. et al. Stage I to IIB Hodgkin's disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy. J. Clin. Oncol. 5:1987;1041-1049.
94. Willet C.G., Linggood R.M., Meyer J. et al. Results of treatment of Stage IA and IIA Hodgkin's disease. Cancer. 59:1987;1107-1111.
95. Mauch P.M., Tarbell N., Weinstein H. et al. Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J. Clin. Oncol. 6:1988;1576-1583.
96. Mazza P., Miniaci G., Lauria F. et al. Prognostic significance of lymphography in stage IIIs Hodgkin's disease (HD). Eur. J. Cancer. Clin. Oncol. 20:1984;1393-1399.
97. Pavlosky S., Maschio M., Santarelli M.T. et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. J. Natl. Cancer Inst. 80:1988;1466-1473.
98. Tubiana M., Attié E., Flamant R. et al. Prognostic factors in 454 cases of Hodgkin's disease. Cancer Res. 31:1971;1801-1810.
99. Young R.C., Canellos G.P., Chabner B.A. et al. Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer. 42:1978;1001-1007.
100. DeVita V.T. The consequences of the chemotherapy of Hodgkin's disease. Cancer. 47:1981;1-13.
101. Dady P.J., McElwain T.J., Austin D.E. et al. Five years' experience with ChlVPP: Effective low-toxicity combination chemotherapy for Hodgkin's disease. Br. J. Cancer. 45:1982;851-859.
102. Hagemeister F.B., Fuller L.M., Velazquez W.S. et al. Stage I and II Hodgkin's disease: Involved-field radiotherapy versus extended-field radiotherapy versus involved-field radiotherapy followed by six cycles of MOPP. Cancer. 66:1982;789-798.
103. Specht L., Nissen N.I. Prognostic significance of tumour burden in Hodgkin's disease PS I and II. Scand. J. Haematol. 36:1986;367-375.
104. Vaughan Hudson B., MacLennan K.A., Bennett M.H. et al. Systemic disturbance in Hodgkin's disease and its relation to histopathology and prognosis (BNLI report No. 39). Clin. Radiol. 38:1987;257-261.
105. Specht L., Nordentoft A.M., Cold S. et al. Tumour burden in early stage Hodgkin's disease: the single most important factor for outcome after radiotherapy. Br. J. Cancer. 55:1987;535-539.
106. Specht L., Nissen N.I. Hodgkin's disease stages I and II with infradiaphragmatic presentation: a rare and prognostically unfavourable combination. Eur. J. Haematol. 40:1988;396-402.
107. Specht L., Nissen N.I. Prognostic factors in Hodgkin's disease stage III with special reference to tumour burden. Eur. J. Haematol. 41:1988;80-87.
108. Specht L., Nissen N.I. Prognostic factors in Hodgkin's disease stage IV. Eur. J. Haematol. 41:1988;359-367.
109. Specht L., Nordentoft A.M., Cold S. et al. Tumour burden as the most important prognostic factor in early stage Hodgkin's disease. Relation to other prognostic factors and implications for choice of treatment. Cancer. 61:1988;1719-1727.
110. Specht L. Prognostic factors in Hodgkin's disease. Dan. Med. Bull. 39:1992;409-422.
111. Specht L. Tumour burden as the main indicator of prognosis in Hodgkin's disease. Eur. J. Cancer. 28A:1992;1982-1985.
112. Hasenclever D., Diehl V. A prognostic score for advanced Hodgkin's disease. N. Engl. J. Med. 339:1998;1506-1514.
113. Lukes R.J., Craver I.F., Hall T.C. et al. Report of the nomenclature committee. Cancer. 26:1966;1311.
114. Butler J.J. Relationship of histological findings to survival in Hodgkin's disease. Cancer Res. 31:1971;1770-1775.
115. Lukes R.J., Butler J.J., Hicks E.B. Natural history of Hodgkin's disease as related to its pathologic picture. Cancer. 19:1966;317-344.
116. Colby T.V., Hoppe R.T., Warnke R.A. Hodgkin's disease: a clinicopathologic study of 659 cases. Cancer. 49:1981;1848-1858.
117. Zittoun R., Audebert A., Hœrni B. et al. Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease. J. Clin. Oncol. 3:1985;207-214.
118. Culine S., Henry-Amar M., Diebold J. et al. Relationship of histological subtype to prognosis in early stage Hodgkin's disease: a review of 312 cases in a controlled clinical trial. Eur. J. Cancer Clin. Oncol. 25:1989;551-556.
119. Bennett M.H., MacLennan K.A., Easterling M.J. et al. The prognostic significance of cellular subtypes in nodular sclerosing Hodgkin's disease: an analysis of 271 non-laparotomised cases (BNLI report No. 22). Clin. Radiol. 34:1983;497-501.
120. MacLennan K.A., Bennett M.H., Tu A. et al. Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. Cancer. 64:1989;1686-1693.
121. MacLennan KA, Bennett MH, Boscq J, et al. The histology and immunohistology of Hodgkin's disease: its relationship to prognosis and clinical behaviour. In: Somers R, Henry-Amar M, Meerwaldt JK, Carde P, editors. Colloque INSERM, vol. 196. Treatment strategy in Hodgkin's disease. Paris: John Libby Eurotext, 1990:17-25.
122. d'Amore E.S., Lee C.K., Aeppli D.M. et al. Lack of prognostic value of histopathologic parameters in Hodgkin's disease, nodular sclerosis type. A study of 123 patients with limited stage disease who had undergone laparotomy and were treated with radiation therapy. Arch. Pathol. Lab. Med. 116:1992;856-861.
123. Hess J.L., Bodis S., Pinkus G. et al. Histopathologic grading of nodular sclerosis Hodgkin's disease. Lack of prognostic significance in 254 surgically staged patients. Cancer. 74:1994;708-714.
124. Sextro M., Diehl V., Franklin J. et al. Lymphocyte predominant Hodgkin's disease: a workshop report. Ann. Oncol. 7(suppl 4):1996;S61-S65.
125. de Mascarel I., Trojani M., Eghbali H. et al. Prognostic value of phenotyping by Ber-H2, Leu-m1, EMA in Hodgkin's disease. Arch. Pathol. Lab. Med. 114:1990;953-955.
126. von Wasielewski R, Mengel M, Fischer R, et al. Classical Hodgkin's disease. Clinical impact of the immunophenotype, Am J Pathol 1997;151:1123-1130.
127. Mortazavi S.H., Bani-Hashemi A., Mozafari M. et al. Value of serum copper measurement in lymphomas and several other malignancies. Cancer. 29:1972;1193-1198.
128. Tessmer C.F., Hrgovcic M., Wilbur J. Serum copper in Hodgkin's disease in children. Cancer. 31:1973;303-315.
129. Thorling E.B., Thorling K. The clinical usefulness of serum copper determinations in Hodgkin's disease. A retrospective study of 241 patients from 1963-1973. Cancer. 38:1976;225-231.
130. Osoba D., Falk J.A., Sousan P. et al. The prognostic value of HLA phenotypes in Hodgkin's disease. Cancer. 46:1980;1825-1832.
131. Schilling R.F., McKnight B., Crowley J.J. Prognostic value of serum lactic dehydrogenase level in Hodgkin's disease. J. Lab. Clin. Med. 99:1982;382-387.
132. Schilling R.F., McKnight B., Crowley J.J. Prognostic value of blood glucose in Hodgkin's disease. J. Clin. Oncol. 2:1984;828-830.
133. Schulof R.S., Bockman R.S., Garofalo J.A. et al. Multivariate analysis of T-cell functional defects and circulating serum factors in Hodgkin's disease. Cancer. 48:1981;964-973.
134. Pizzolo G., Chilosi M., Vinante F. et al. Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease. Br. J. Cancer. 55:1985;427-428.
135. Pui C.H., Ip S.H., Thompson E. et al. High serum interleukin-2 receptor levels correlate with a poor prognosis in children with Hodgkin's disease. Leukemia. 3:1989;481-484.
136. Ambrosetti A., Nadali G., Vinante F. et al. Serum levels of soluble interleukin-2 receptor in Hodgkin's disease. Cancer. 72:1993;201-206.
137. Gobbi P.G., Gendarini C., Crema A. et al. Serum albumin in Hodgkin's disease. Cancer. 55:1985;389-393.
138. Pui C.H., Ip S.H., Thompson E. et al. Increased serum CD8 antigen level in childhood Hodgkin's disease relates to advanced stage and poor treatment outcome. Blood. 73:1989;209-213.
139. Gause A., Pohl C., Tschiersch A. et al. The prognostic value of Hodgkin-associated soluble antigen (CD30s) in the sera of patients with Hodgkin's disease. Proc. Am. Soc. Clin. Oncol. 9:1990;258.
140. Pizzolo G., Vinante F., Chilosi M. et al. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage. Br. J. Haematol. 75:1990;282-284.
141. Cabanillas F. A review and interpretation of cytogenetic abnormalities identified in Hodgkin's disease. Hematol. Oncol. 6:1988;271-274.
142. Schouten H.C., Sanger W.G., Duggen M. et al. Chromosomal abnormalities in Hodgkin's disease. Blood. 73:1989;2149-2154.
143. MacLennan K.A., Vaughan Hudson B., Jelliffe A.M. et al. The pretreatment peripheral blood lymphocyte count in 1100 patients with Hodgkin's disease: the prognostic significance and the relationship to the presence of systemic symptoms. Clin. Oncol. 7:1981;333-339.
144. Wedelin C., Björkholm M., Holm G. et al. Lymphocyte function in untreated Hodgkin's disease: an important predictor of prognosis. Br. J. Cancer. 45:1982;70-79.
145. Armstrong A.A., Alexander F.E., Paes R.P. et al. Association of Epstein-Barr virus with pediatric Hodgkin's disease. Am. J. Pathol. 142:1993;1683-1688.
146. Herbst H., Pallesen G., Weiss L.M. et al. Hodgkin's disease and Epstein-Barr virus. Ann. Oncol. 3(suppl 4):1992;S27-S30.
147. Khan G., Norton A.J., Slavin G. Epstein-Barr virus in Hodgkin's disease. Cancer. 71:1993;3124-3129.
148. Bosq J, Audouin J, Henry-Amar M, et al. EBV infection is predictive for a higher probability of treatment failure after irradiation in early stages Hodgkin's disease. Fourth International Symposium of Hodgkin's Lymphoma, Cologne, 28 mars-1 avril 1998. (for the EORTC Lymphoma Cooperative Group).
149. Boiocchi M., de Re V., Dolecetti R. et al. Association of Epstein-Barr virus genome with mixed cellularity and cellular phase nodular sclerosis Hodgkin's disease subtypes. Ann. Oncol. 3:1992;307-310.
150. Jarrett A.F., Armstrong A.A., Alexander E. Epidemiology of EBV and Hodgkin's lymphoma. Ann. Oncol. 7(suppl 4):1996;S5-S10.
151. Hummel M., Anagnostopouloos I., Dallenbach F. et al. EBV infection patterns in Hodgkin's disease and normal lymphoid tissue: expression and cellular localization of EBV gene products. Br. J. Haematol. 82:1992;689-694.
152. Huh J., Park C., Juhng S. et al. A pathologic study of Hodgkin's disease in Korea and its association with the Epstein-Barr virus infection. Cancer. 77:1996;949-955.
153. Belkaid M.I., Zerhouni F., Beljord K. et al. Association du virus d'Epstein-Barr à la maladie de Hodgkin: comparaison entre patients algériens et français. Bull. Cancer. 82:1995;357-363.
154. Wedelin C., Björkholm M., Biberfeld P. et al. Prognostic factors in Hodgkin's disease with special refrence to age. Cancer. 53:1984;1202-1208.
155. Terblanche A.P.S., Falkson G., Matzner L. The prognostic significance of age in patients with advanced Hodgkin's disease. Eur. J. Clin. Oncol. 24:1988;1805-1809.
156. Carde P, Bergsagel DE, Nissen NI, et al. The treatment of advanced Hodgkin's disease. In: Somers R, Henry-Amar M, Meerwaldt JK, Carde P, editors. Colloque INSERM, vol. 196. Treatment strategy in Hodgkin's disease. Paris: John Libbey Eurotext, 1990; 17-25.
157. DeVita V.T., Sepick A.A., Carbone P.P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann. Inter. Med. 73:1970;881-895.
158. Bonadonna G., Zucali R., Monfardini S. et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine and imidazole carboxamide versus MOPP. Cancer. 36:1975;252-259.
159. DeVita V.T., Lewis B.R., Rosencweig M. et al. The chemotherapy of Hodgkin's disease. Past experience and future directions. Cancer. 42:1978;979-990.
160. DeVita Jr V.T.J., Hubbard S.M., Longo D.L. The chemotherapy of lymphoma: looking back, moving forward The Richard and Hinda Rosenthal award lecture. Cancer Res. 47:1987;5810-5824.
161. Arseneau J.C., Sponzo R.W., Levin D.L. et al. Non-lymphomatous malignant tumours complicating Hodgkin's disease: possible association with intensive therapy. N. Engl. J. Med. 287:1972;1119-1122.
162. Kaldor J.M., Day N.E., Clarke E.A. et al. Leukemia following Hodgkin's disease. N. Engl. J. Med. 322:1990;7-13.
163. Chapman R.M., Sutcliffe S.B., Rees L. et al. Cyclical combination chemotherapy and gonadal function: Retrospective study in males. Lancet. 1:1979;285-289.
164. Chapman R.M., Sutcliffe S.M., Malpas J.S. Male gonadal dysfunction in Hodgkin's disease. A prospective study. J. Am. Med. Assoc. 245:1981;1323-1328.
165. Whitehead E., Shalet S.M., Blackledge G. et al. The effect of Hodgkin's disease and combination chemotherapy on gonadal function in the adult male. Cancer. 49:1982;418-422.
166. da Cunha M.F., Meistrich M.L., Fuller L.M. et al. Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy. J. Clin. Oncol. 2:1984;571-577.
167. van Leeuwen F.E., Chorus A.M., van den Belt Dusebout A.W. et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J. Clin. Oncol. 12:1994;1063-1073.
168. Prosnitz L.R., Farber L.R., Fischer J.J. et al. Long term remissions with combined modality therapy for advanced Hodgkin's disease. Cancer. 37:1976;2826-2833.
169. McElwain T.J., Toy J., Smith I.E. et al. A combination of chlorambucil, vinblastine, procarbazine and prenisolone for treatment of Hodgkin's disease. Br. J. Cancer. 36:1977;276-280.
170. Anonymous ChlVPP therapy for Hodgkin's disease: experience of 960 patients. The International ChlVPP Treatment Group. Ann. Oncol. 6:1995;167-172.
171. ChlVPP therapy for Hodgkin's disease: experience of 960 patients. Ann. Oncol. 6:1995;167-172.
172. Vose J., Armitage J., Weisenburger D. et al. ChlVPP. An effective and well-tolerated alternative to MOPP therapy for Hodgkin's disease. Am. J. Clin. Oncol. 11:1988;423-426.
173. Sutcliffe S.B., Wrigley P.F., Peto J. et al. MVPP chemotherapy regimen for advanced Hodgkin's disease. Br. Med. J. 1:1978;679-683.
174. Radford J.A., Crowther D., Rohatiner A.Z. et al. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease. J. Clin. Oncol. 13:1995;2379-2385.
175. Bloomfield C.D., Weiss R.B., Fortuny I. et al. Combined chemotherapy with cyclo-phosphamide, vinblastine, procarbazine and prednisone (CVPP) for patients with advanced Hodgkin's disease. An alternative program to MOPP. Cancer. 38:1976;42-48.
176. Morgenfeld M., Somoza N., Magnasco J. et al. Combined chemotherapy cyclophos-phamide, vinblastine, procarbazine and prednisone (CVPP) versus CVPP plus CCNU (CCVPP) in Hodgkin's disease. Cancer. 43:1979;1579-1586.
177. Pavlovsky S., Schvartzman E., Lastiri F. et al. Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin's disease. J. Clin. Oncol. 15:1997;2652-2658.
178. Chauvergne J., Hœrni B., Hœrni-Simon G. et al. Chimiothérapie de la maladie de Hodgkin associant procarbazine, vinblastine, cyclophosphamide et méthylpredniso-lone. Analyse d'une série de 124 cures. Z. Krebsforsch. 80:1973;179-188.
179. Lagarde C., Chauvergne J., Hœrni B. et al. Traitement des stades cliniques I et II de la maladie de Hodgkin. Résultats obtenus chez 100 malades par association à la radiothérapie d'un ou deux cycles de chimiothérapie. Acta Haematol. 55:1976;257-264.
180. Durant J.R., Gams R.A., Velez-Garcia E. et al. BCNU, velban, cyclophosphamide, procarbazine and prednisone (BVCPP) in advanced Hodgkin's disease. Cancer. 42:1978;2101-2110.
181. Hancock B.W., Vaughan Hudson G., Vaughan Hudson B. et al. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial. J. Clin. Oncol. 10:1992;1252-1258.
182. Goldman J.M., Dawson A.A. Combination therapy for advanced resistant Hodgkin's disease. Lancet. 2:1975;1224-1227.
183. Longo D.L. The use of chemotherapy in the treatment of Hodgkin's disease. Semin. Oncol. 17:1990;716-735.
184. Hancock S.L., Hoppe R.T., Horning S.J. et al. Intercurrent death after Hodgkin's disease therapy in radiotherapy and adjuvant MOPP trials. Ann. Intern. Med. 109:1988;183-189.
185. Henry-Amar M. Quantitative risk of second cancer in patients in first complete remission from early stages of Hodgkin's disease. NCI Monogr. 6:1988;65-72.
186. Henry-Amar M. Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease. Ann. Oncol. 3(suppl 4):1992;117-128.
187. Henry-Amar M. Seconds cancers après traitement pour maladie de Hodgkin: l'expérience de l'nternational Database on Hodgkin's disease (IDHD). Bull. Cancer (Paris). 79:1992;389-391.
188. Valagussa P. Second neoplasms following treatment of Hodgkin's disease. Curr. Opin. Oncol. 5:1993;805-811.
189. Boivin J.F., Hutchison G.B., Zauber A.G. et al. Incidence of second cancers in patients treated for Hodgkin's disease [see comments]. J. Natl. Cancer Inst. 87:1995;732-741.
190. Pedersen-Bjergaard J., Specht L., Larsen S.O. et al. Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet. 2:1987;83-88.
191. Tucker M.A., Meadows A.T., Boice J.D. et al. Leukemia after therapy with alkylating agents for childhood cancer. J. Natl. Cancer Inst. 78:1987;459-464.
192. Valagussa P., Santoro A., Fossati-Bellani F. et al. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J. Clin. Oncol. 4:1986;830-837.
193. Carde P., Hagenbeek A., Hayat M. et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J. Clin. Oncol. 11:1993;2258-2272.
194. Somers R., Carde P., Henry-Amar M. et al. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J. Clin. Oncol. 12:1994;279-287.
195. Canellos G.P. Current strategies for early Hodgkin's disease. Ann. Oncol. 7(suppl 4):1996;S91-S93.
196. Eghbali H, Bonichon F, David B et al. Combination of ABVD and radiotherapy in early stages of Hodgkin's disease: analysis of a series of 94 patients. Radiother. Oncol. 18:1990;127-136.
197. Hirsch A., Vander Els N., Straus D.J. et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J. Clin. Oncol. 14:1996;1297-1305.
198. Boivin J.F., Hutchison G.B. Coronary heart disease mortality after irradiation for Hodgkin's disease. Cancer. 49:1982;2470-2475.
199. Boivin J.F., Hutchison G.B., Lubin J.H. et al. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer. 69:1992;1241-1247.
200. King V., Constine L.S., Clark D. et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease. Int. J. Radiat. Oncol. Biol. Phys. 36:1996;881-889.
201. Henry-Amar M., Joly F. Late complications after Hodgkin's disease. Ann. Oncol. 7(suppl 4):1996;S115-S126.
202. Vrignaud P., Eghbali H., Hœrni B. et al. Phamacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's disease. Eur. J. Cancer Clin. Oncol. 21:1985;1307-1313.
203. Robert J., Vrignaud P., Nguyen T. et al. Comparative phamacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer. Cancer Treat. Rep. 69:1985;633-640.
204. Zittoun R., Eghbali H., Audebert A. et al. Association d'épirubicine, bleomycine, vinblastine et prednisone (EBVP) avant radiothérapie dans les stades localisés de la maladie de Hodgkin. Essai de phase II. Bull. Cancer (Paris). 74:1987;151-157.
205. Hœrni B., Orgerie M.B., Eghbali H. et al. Nouvelle association d'epirubicine, bleomycine, vinblastine et prednisone (EBVP II) avant radiotherapie dans la maladie de Hodgkin. Essai de phase II chez 50 malades. Bull. Cancer (Paris). 75:1988;789-794.
206. Hœrni B., Orgerie M.B., Eghbali H. et al. Novel combination of epirubicin, bleomycin, vinblastine and prednisone (EBVP II) before radiotherapy in localized stage (I-IIIA) of Hodgkin's disease. Early results in 100 consecutive patients. J. Cancer Res. Clin. Oncol. 117:1991;377-380.
207. Noordijk E.M., Carde P., Mandard A.M. et al. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie. Ann. Oncol. 5(suppl 2):1994;107-112.
208. Hagenbeek A, Carde P, Noordijk E, et al.@ Prognostic factor tailored treatment of early stage Hodgkin's disease. Results from a prospective randomised phase III trial in 762 patients (H7 study). Blood 1997;90(suppl 1):585a, abs 2603.
209. Bonadonna G., Valagussa P., Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. Ann. Intern. Med. 104:1986;739-746.
210. Connors J.M., Klimo P. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease. Semin. Hematol. 24:1987;35-40.
211. Viviani S., Bonadonna G., Santoro A. et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: 10-year results. J. Clin. Oncol. 14:1996;1421-1430.
212. Connors J.M., Klimo P., Adams G. et al. Treatment of advanced Hodgkin's disease with chemotherapy. Comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 15:1997;1638-1645.
213. Canellos G.P., Anderson J.R., Propert K.J. et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD [see comments]. N. Engl. J. Med. 327:1992;1478-1484.
214. Lagarde P., Eghbali H., Bonichon F. et al. Brief chemotherapy associated with extended field radiotherapy in Hodgkin's disease. Long-term results in a series of 102 patients with clinical stages I-IIIA. Eur. J. Cancer Clin. Oncol. 24:1988;1191-1198.
215. Eghbali H., Hœrni-Simon G., Durand M. et al. Hodgkin's disease treated by chemotherapy and large field irradiation. Acta Radiol. Oncol. 17:1978;289-295.
216. Canellos G.P., Anderson J.R., Peterson B.A. et al. EVA: etoposide, vinblastine, doxorubicin (Adriamycine): an effective regimen for the treatment of Hodgkin's disease in relapse following MOPP: a study of the Cancer and Leukemia group B [abstract]. Proc. Am. Soc. Clin. Oncol. 10:1991;273.
217. Canellos G.P., Petroni G.R., Barcos M. et al. Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B. J. Clin. Oncol. 13:1995;2005-2011.
218. Carde P. Chemotherapy of Hodgkin's disease. Nouv. Rev. Fr. Hematol. 32:1990;169-173.
219. Horning S.J., Hoppe R.T., Hancock S.L. et al. Vinblastine, bleomycine, and methotrexate: an effective adjuvant in favorable Hodgkin's disease. J. Clin. Oncol. 6:1988;1822-1831.
220. Hagemeister F.B., Cabanillas F., Velasquez W. et al. NOVA: A novel chemotherapic regimen with minimal toxicity for treatment of Hodgkin's disease. Semin. Oncol. 17:1990;34-40.
221. Hagemeister F.B., Purugganan R., Fuller L. et al. Treatment of early stages of Hodgkin's disease with novantrone, vincristine, vinblastine, prednisone, and radio-therapy. Semin. Hematol. 31(suppl 3):1994;36-43.
222. Horning S.J., Ang P.T., Hoppe R.T. et al. The Stanford experience with combined procarbazine, Alkeran and vinblastine (PAVe) and radiotherapy for locally extensive and advanced stage Hodgkin's disease. Ann. Oncol. 3:1992;747-754.
223. Brusamolino E., Orlandi E., Canevari A. et al. Results of CAV regimen (CCNU, melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease. Ann. Oncol. 5:1994;427-432.
224. Santoro A., Bonfante V., Viviani S. et al. Salvage chemotherapy in relapsing Hodgkin's disease. Proc. Am. Soc. Clin. Oncol. 3:1984;254.
225. Zinzani P.L., Barbieri E., Bendandi M. et al. CEP regimen (CCNU, etoposide, prednimustine) for relapsed/refractory Hodgkin's disease. Tumori. 80:1994;438-442.
226. Wiernik P.H., Schiffer C.A. Long-term follow-up of advanced Hodgkin's disease patients treated with a combination of streptozotocin, lomustine (CCNU), doxorubicin and bleomycin (SCAB). J. Cancer Res. Clin. Oncol. 114:1988;105-107.
227. Fairey A.F., Mead G.M., Jones H.W. et al. CAPE/PALE salvage chemotherapy for Hodgkin's disease patients relapsing within 1 year of ChlVPP chemotherapy. Ann. Oncol. 4:1993;857-860.
228. Hill M., Milan S., Cunningham D. et al. Evaluation of the efficacy of VEEP regimen in adults Hodgkin's disease with assessment of gonadal and cardiac toxicity. J. Clin. Oncol. 13:1995;387-395.
229. O'Brien M.E., Pinkerton C.R., Kingston J. et al. 'VEEP' in children with Hodgkin's disease: a regimen to decrease late sequelae. Br. J. Cancer. 65:1992;756-760.
230. Simmonds P.D., Mead G.M., Sweetenham J.W. et al. PACE BOM chemotherapy: a 12-week regimen for advanced Hodgkin's disease. Ann. Oncol. 8:1997;259-266.
231. Bartlett N.L., Rosenberg S.A., Hoppe R.T. et al. Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J. Clin. Oncol. 13:1995;1080-1088.
232. Diehl V., Sieber M., Rüffer U. et al. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. Ann. Oncol. 8:1997;143-148.
233. Diehl V., Franklin J., Hasenclever D. et al. BEACOPP: a new regimen for advanced Hodgkin's disease. Ann. Oncol. 9(suppl 5):1998;S67-S71.
234. Reece D. Early autologous bone marrow transplantation (ABMT) in the treatment of Hodgkin's disease. Leuk. Lymphoma. 15(suppl 1):1995;55-57.
235. Pfreundschuh M.G., Rueffer U., Lathan B. et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. J. Clin. Oncol. 12:1994;580-586.
236. Fermé C., Bastion Y., Lepage E. et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann. Oncol. 6:1995;543-549.
237. Colwill R., Crump M., Couture F. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J. Clin. Oncol. 13:1995;396-402.
238. Schellong G., Riepenhausen M., Creutzig U. et al. Low risk of secondary leukemias after chemotherapy without mechloretamine in childhood Hodgkin's disease. J. Clin. Oncol. 15:1997;2247-2253.
239. Bennett M.H., MacLennan K.A. Vaughan Hudson G from the British National Lymphoma Investigation. Non-Hodgkin's lymphoma arising in patients treated for Hodgkin's disease in the BNLI: a 20-year experience. Ann. Oncol. 2(suppl 2):1991;83-92.
240. Krikorian J.G., Burke J.S., Rosenberg S.A. et al. Occurrence of non-Hodgkin's lymphoma after therapy for Hodgkin's disease. N. Engl. J. Med. 300:1979;452-458.
241. van Leeuwen F.E., Klokman W.J., Hagenbeek A. et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J. Clin. Oncol. 12:1994;312-325.
242. Horning S.J., Adhiraki A., Rizk N. et al. Effect of treatment for Hodgkin's disease on pulmonary function: results of a prospective study. J. Clin. Oncol. 12:1994;297-305.
243. Valagussa P., Santoro A., Bonadonna G. Thyroid, pulmonary, and cardiac sequelae after treatment of Hodgkin's disease. Ann. Oncol. 3(suppl 4):1992;S111-S115.
244. Lund M.B., Kongerud J., Nome O. et al. Lung function impairment in long-term survivors of Hodgkin's disease. Ann. Oncol. 6:1995;495-501.
245. Gilbert R. Radiotherapy in Hodgkin's disease (malignant granulomatosis). Am. J. Roentgenol. 41:1939;198-241.
246. Peters M.V. A study of survivals in Hodgkin's disease treated radiologically. Am. J. Roentgenol. 63:1950;299-311.
247. Peters M.V., Middlemiss K.C.H. A study of Hodgkin's disease treated by irradiation. Am. J. Roentgenol. 79:1958;114-121.
248. Peters M.V., Alison R.E., Bush R.S. Natural history of Hodgkin's disease related to staging. Cancer. 19:1966;308-316.
249. Kaplan H.S. The radical radiotherapy of regionally localized Hodgkin's disease. Radiology. 78:1962;553-561.
250. Kaplan H.S. Hodgkin's disease: unfolding concepts concerning its nature, management and prognosis. Cancer. 45:1980;2439-2474.
251. Richaud P. Maladie de Hodgkin: quelle dose d'irradiation délivrer? Bull. Cancer (Paris). 79:1993;185-187.
252. Janjan N.A., Zellmer D.L. Calculated risk of breast cancer following mantle irradiation determined by measured dose. Cancer Detect. Prev. 16(5-6):1992;273-282.
253. Shapiro C.L., Mauch P.M. Radiation-associated breast cancer after Hodgkin's disease: risks and screening in perspective [editorial; comment]. J. Clin. Oncol. 10:1992;1662-1665.
254. Swerdlow A.J., Douglas A.J., Hudson G.V. et al. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. Br. Med. J. 304:1992;1137-1143.
255. Swerdlow A.J., Douglas A.J., Vaughan Hudson G. et al. Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy. Br. J. Cancer. 68:1993;1006-1011.
256. Hancock S.L., Tucker M.A., Hoppe R.T. Breast cancer after treatment of Hodgkin's disease. J. Natl. Cancer Inst. 85:1993;25-31.
257. Bhatia S., Robinson L.L., Oberling O. et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N. Engl. J. Med. 334:1996;745-751.
258. Aisenberg A.C., Finkelstein D.M., Doppke K.P. et al. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer. 79:1997;1203-1210.
259. van Leeuwen F.E., Klokman W.J., Stovall M. et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease [see comments]. J. Natl. Cancer Inst. 87:1995;1530-1537.
260. Scholz K.H., Herrmann C., Tebbe U. et al. Myocardial infarction in young patients with Hodgkin's disease - potential pathogenic role of radiotherapy, chemotherapy, and splenectomy. Clin. Investig. 71:1993;57-64.
261. Hancock S.L., Donaldson S.S., Hoppe R.T. Cardiac disease following treatment of Hodgkin's disease in children and adolescents [see comments]. J. Clin. Oncol. 11:1993;1208-1215.
262. Glanzmann C., Huguenin P., Lutolf U.M. et al. Cardiac lesions after mediastinal irradiation for Hodgkin's disease. Radiother. Oncol. 30:1994;43-54.
263. Gustavsson A., Eskilsson J., Landberg T. et al. Long-term effects on pulmonary function of mantle radiotherapy in patients with Hodgkin's disease. Ann. Oncol. 3:1992;455-461.
264. Gottdiener J.S., Katin M.J., Borer J.S. et al. Late cardiac effects of therapeutic mediastinal irradiation. N. Engl. J. Med. 308:1983;569-572.
265. Perrault D.J., Levy M., Herman J.D. et al. Echocardiographic abnormalities following cardiac radiation. J. Clin. Oncol. 3:1985;546-551.
266. Jenkin R.D.T., Berry M.P. Hodgkin's disease in children. Semin. Oncol. 7:1980;202-211.
267. Andrieu J.M., Dana M., Desprez-Curley J.P. et al. MOPP chemotherapy plus irradiation for Hodgkin's disease, stages IA to IIIB. Long-term results of the prospective trial H72 (1972-1976, 334 patients). Hematol. Oncol. 3:1985;219-231.
268. Hœrni B., Zittoun R., Rojouan J. et al. Retentissement psychosocial du traitement de la maladie de Hodgkin. Appréciation par questionnaire auprès de 150 malades. Bull. Cancer (Paris). 73:1986;620-626.
269. Oberlin O., Leverger G., Pacquement H. et al. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology. J. Clin. Oncol. 10:1992;1602-1608.
270. Donaldson S.S., Link M.P. Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease. J. Clin. Oncol. 5:1987;742-749.
271. Hudson M.M., Greenwald C., Thompson E. et al. Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease. J. Clin. Oncol. 11:1993;100-108.
272. Fitoussi O, Tchen N, Soubeyran P, Eghbali H. Semen analysis and cryopreservation before treatment in Hodgkin's disease. 23rd ESMO Congress. Athens, November 6-10, 1998.
273. Cimino G., Biti G.P., Anselmo A.P. et al. MOPP chemotherapy versus extended radiotherapy in the management of pathological stages I-IIA Hodgkin's disease. J. Clin. Oncol. 7:1989;732-737.
274. Biti GP, Cimino G, Cartoni C, Magrini, et al. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: 8-year update of an Italian prospective randomized study [see comments]. J Clin Oncol 10:378-382, 1992.
275. Longo D.L., Glatstein E., Duffey P.L. et al. Radiation treatment versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: 7-year results of a prospective randomized trial. J. Clin. Oncol. 9:1991;906-917.
276. Hunger S.P., Link M.P., Donaldson S.S. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience. J. Clin. Oncol. 12:1994;2160-2166.
277. Specht L., Gray R.G., Clarke M.J. et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: A meta-analysis of 23 randomized trials involving 3888 patients. J. Clin. Oncol. 16:1998;830-843.
278. Raemaekers J., Burgers M., Henry-Amar M. et al. Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie. Ann. Oncol. 8(suppl 1):1997;111-114.
279. Bodis S., Henry-Amar M., Bosq J. et al. Late relapse in early-stage Hodgkin's disease patients enrolled on European Organization for Research and Treatment of Cancer protocols. J. Clin. Oncol. 11:1993;225-232.
280. Herman T.S., Hoppe R.T., Donaldson S.S. et al. Late relapse among patients treated for Hodgkin's disease. Ann. Intern. Med. 102:1985;292-297.
281. Roach M., Brophy N., Cox R. et al. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease. J. Clin. Oncol. 8:1990;623-629.
282. Healey E.A., Tarbell N.J., Kalish L.A. et al. Prognostic factors for patients with Hodgkin disease in first relapse [see comments]. Cancer. 71:1993;2613-2620.
283. Brice P., Bastion Y., Divine P. et al. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients. Cancer. 78:1996;1293-1299.
284. Specht L., Horwich A., Ashley S. Salvage of relapse with Hodgkin's disease in clinical stages I or II who were staged with laparotomy and initially treated with radiotherapy alone. A report from the International Database on Hodgkin's disease. Int. J. Radiat. Oncol. Biol. Phys. 30:1994;805-811.
285. Angelo M., Carella A.M. Autologous stem cell transplantation (ASCT) in Hodgkin's disease: present status. Pathol. Biol. Paris. 41:1993;107-109.
286. Anonymous A. ABMT recommended for relapsed Hodgkin's disease, but better overall survival not yet proved. Oncol. Hunting. 10:1996;593-594.
287. Armitage J.O. Early bone marrow transplantation in Hodgkin's disease. Ann. Oncol. 5(suppl 2):1994;161-163.
288. Armitage J.O. Treatment strategies for patients with relapsed or refractory Hodgkin's disease [editorial; comment]. Ann. Oncol. 6:1995;517-518.
289. Armitage J.O., Bierman P.J., Vose J.M. et al. Autologous bone marrow transplantation for Hodgkin's disease. J. Hematother. 4:1995;61-62.
290. Bierman P.J., Bagin R.G., Jagannath S. et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients. Ann. Oncol. 4:1993;767-773.
291. Bierman P.J., Anderson J.R., Freeman M.B. et al. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. Ann. Oncol. 7:1996;151-156.
292. Brice P., Bouabdallah R., Moreau P. et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moelle. Bone Marrow Transpl. 20:1997;21-26.
293. Chopra R., McMillan A.K., Linch D.C. et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center 8-year study of 155 patients. Blood. 81:1993;1137-1145.
294. Gianni A.M., Siena S., Bregni M. et al. High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease: a 6-year update. Ann. Oncol. 4:1993;889-891.
295. Horning S.J., Chao N.J., Negrin R.S. et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood. 89:1997;801-813.
296. Pezner R.D., Nademanee A., Forman S.J. High-dose therapy and autologous bone marrow transplantation for Hodgkin's disease patients with relapses potentially treatable by radical radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 33:1995;189-194.
297. Reece D.E., Phillips G.L. Intensive therapy and autologous stem cell transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Leuk. Lymphoma. 21:1996;245-253.
298. Sureda A., Mataix R., Hernandez Navarro F. et al. Autologous stem cell transplantation for poor prognosis Hodgkin's disease in first complete remission: a retrospective study from the Spanish GEL-TAMO cooperative group. Bone Marrow Transpl. 20:1997;283-288.
299. Linch D.C., Winfield D., Goldstone A.H. et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 341:1993;1051-1054.
300. Jones R.J., Piantadosi S., Mann R.B. et al. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J. Clin. Oncol. 8:1990;527-537.
301. Carella A.M., Congiu A.M., Gaozza E. et al. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an italian study group report. J. Clin. Oncol. 6:1988;1411-1416.
302. Federico M., Clò V., Carella A.M. et al. High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's disease responding to first-line therapy. Analysis of clinical characteristics of 51 patients enrolled in the HD01 protocol. Leukemia. 10(suppl 2):1996;S69-S71.
303. Carella A.M., Carlier P., Congiu A. et al. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol. Bone Marrow Transpl. 8:1991;99-103.
304. Carella A.M., Prencipe E., Pungolino E. et al. Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in firts remission after MOPP/ABVD. Leuk. Lymphoma. 21:1996;63-90.
305. Moreau P., Milpied N., Méchinaud-Lacroix F. et al. Eearly intensive therapy with autotransplantation for high-risk Hodgkin's disease. Leuk. Lymphoma. 12:1993;51-58.
306. Weiner M.A., Leventhal B., Brecher M.L. et al. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J. Clin. Oncol. 15:1997;2769-2779.
307. Ekert H., Waters K.D., Smith P.J. et al. Treatment with MOPP or ChlVPP chemotherapy only for all stages of chilhood Hodgkin's disease. J. Clin. Oncol. 6:1988;1845-1850.
308. van den Berg H., Stuve W., Behrendt H. Treatment of Hodgkin's disease in children with alternating mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) courses without radiotherapy. Med. Ped. Oncol. 29:1997;23-27.
309. Lokich J.J., Pinkus G.S., Moloney W.C. Hodgkin's disease in the elderly. Oncology. 29:1974;484-500.
310. Mir R., Anderson J., Strauchen J. et al. Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B. Cancer. 71:1993;1857-1866.
311. Austin-Seymour M.M., Hoppe R.T., Cox R.S. et al. Hodgkin's disease in patients over 60 years old. Ann. Intern. Med. 100:1984;13-18.
312. Eghbali H., Hœrni-Simon G., de Mascarel I. et al. Hodgkin's disease in the elderly. Cancer. 53:1984;2191-2193.
313. Stewart Jr H.L., Monto R.W. Hodgkin's disease and pregnancy. Am. J. Obstet. Gynecol. 63:1952;570-578.
314. Tubiana M. Problèmes posés par l'irradiation des femmes enceintes. Effets des radiations ionisantes sur l'embryon et le foetus. Bull. Cancer (Paris). 66:1979;155-164.
315. Jacobs C., Donaldson S.S., Rosenberg S.A. et al. Management of the pregnant patients with Hodgkin's disease. Ann. Inten. Med. 95:1981;669-675.
316. Woo S.Y., Fuller L.M., Cundiff J.H. et al. Radiotherapy during pregnancy for clinical stages IA-IIA Hodgkin's disease. Int. J. Radiat. Oncol. Biol. Phys. 23:1992;407-412.
317. Delmer A., Bauduer F., Ajchenbaum Cymbalista F. et al. Grossesse et hémopathies malignes: approche thérapeutique. Bull. Cancer (Paris). 81:1994;277-286.
318. Hessol N.A., Katz M.H., Liu S.P. et al. Increased incidence of Hodgkin's disease in homosexual men with HIV infection. Ann. Inten. Med. 117:1992;309-311.
319. Hajjar M., Lacoste D., Broussard G. et al. Non-acquired immune deficiency syndrome-defining malignancies in a hospital-based cohort of human immunodeficiency virus-infected patients: Bordeaux, France, 1985-1991. J. Natl. Cancer Inst. 84:1992;1593-1595.
320. Lacoste D., Dabis F., Boulogne N. et al. Cancer incidence in a cohort of human immunodeficiency virus seroconverters (letter). Cancer. 82:1998;996-998.
321. Roithmann S., Tourani J.M., Gastaut J.A. et al. Maladie de Hodgkin survenant au cours de l'infection a VIH: caractéristiques cliniques et évolution. Registre français des tumeurs associées à l'infection à VIH. Bull. Cancer (Paris). 79:1992;873-882.
322. Tirelli U., Errante D., Vaccher E. et al. Hodgkin's disease in 92 patients with HIV infection: the Italian experience. GICAT (Italian Cooperative Group on AIDS and Tumors). Ann. Oncol. 3(suppl 4):1992;69-72.
323. Andrieu J.M., Roithmann S., Tourani J.M. et al. Hodgkin's disease during HIV1 infection: the French registry experience. French Registry of HIV-associated Tumors. Ann. Oncol. 4:1993;635-641.
324. Tirelli U., Errante D., Dolcetti R. et al. Hodgkin's disease and human immuno-deficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J. Clin. Oncol. 13:1995;1758-1767.
325. Levy R., Colonna P., Tourani J.M. et al. Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-associated tumors. Leuk. Lymphoma. 16:1995;451-456.
326. Ames E.D., Metroka C.E., Goldberg A.F. Hodgkin's disease and HIV (letter). Ann. Intern. Med. 118:1993;313.
327. Ree H.J., Strauchen J.A., Khan A.A. et al. Human immunodeficiency virus-associated Hodgkin's disease. Cancer. 67:1991;1614-1621.
328. Rubio R. Hodgkin's disease associated with human immunodeficiency virus infection. A clinical study of 46 cases. Cooperative Study Group of Malignancies Associated with HIV Infection of Madrid. Cancer. 73:1994;2400-2407.
329. Errante D, Tirelli U, Gastaldi R et al. Combined antineoplastic and antiretroviral therapy for patients with Hodgkin's disease and human immunodeficiency virus infection. A prospective study of 17 patients. The Italian Cooperative Group on AIDS and Tumors (GICAT). Cancer. 73:1994;437-444.
330. Errante D., Zagonel V., Vaccher E. et al. Hodgkin's disease in patients with HIV infection and in the general population: comparison of clinicopathological features and survival. Ann. Oncol. 5(suppl 2):1994;37-40.
331. Hair L.S., Rogers J.D., Chadburn A. et al. Intracerebral Hodgkin's disease in a human immunodeficiency virus-seropositive patient. Cancer. 67:1991;2931-2938.
332. Monfardini S., Tirelli U., Vaccher E. et al. Hodgkin's disease in 63 intravenous drug users infected with human immunodeficiency virus. Ann. Oncol. 2(suppl 2):1991;201-205.